Slide 1: Pacific Edge: Introduction & FY26 Results
PACIFIC EDGE: INTRODUCTION & FY26 RESULTS Dr Peter Meintjes Chief Executive Officer Grant Gibson Chief Financial Officer 1
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation has been prepared by Pacific Edge Limited (PEL ) solely PEL’s current views with respect to future events. Forward-looking Investment risk to provide interested parties with further information about PEL and its statements, by their very nature, invo
Slide 3: Introduction to Pacific Edge
INTRODUCTION TO PACIFIC EDGE 3
Slide 4: Snapshot: Pacific Edge - The First Mover in Bladder Cancer Diagnostics
SNAPSHOT: PACIFIC EDGE - THE FIRST MOVER IN BLADDER CANCER DIAGNOSTICS MAJOR GROWTH CATALYST: DRAFT MEDICARE COVERAGE PROPOSED IN MAY 2026 US$10.2b4 Global Market Opportunity SUBSTANTIAL MARKET GROWTH CATALYST WITH SCIENCE, TECH AND IP CLINICAL EVIDENCE OPPORTUNITY MEDICARE COVERAGE Cxbladder tests
Slide 5: Bladder Cancer – A Significant Global Healthcare Challenge
BLADDER CANCER – A SIGNIFICANT GLOBAL HEALTHCARE CHALLENGE AN INVASIVE STATUS QUO – A NON-INVASIVE OPPORTUNITY CYSTOSCOPY CXBLADDER TEST 1st 6th 9th Costliest cancer to Most common Most common treat on a per- cancer in men2 cancer world-wide2 patient basis1 Source: Nursing Skills ~614K >220K >50% •
Slide 6: Cxbladder: Tests to Rule Out Cancer or Prioritize Patients
CXBLADDER: TESTS TO RULE OUT CANCER OR PRIORITIZE PATIENTS THE PATIENT CARE PATHWAY >130,000 >5,000 >30 Grade A Patients that have used Urologists that have ordered Publications demonstrating AV, Evidence rating by the AUA4 in its Cxbladder Cxbladder CV or CU evidence5 2025 Microhematuria Guideline
Slide 7: Driving Economic Value for Patients, Hospitals and Payers
DRIVING ECONOMIC VALUE FOR PATIENTS, HOSPITALS AND PAYERS CXBLADDER DELIVERS CLINICAL UTILITY, PATIENT SATISFACTION AND ECONOMIC VALUE CANCER INCIDENCE IN MICROHEMATURIA PATIENTS CYSTOSCOPIES SAFELY AVOIDED USING CXBLADDER No cystoscopy Cystoscopy No cancer No cancer Cystoscopy No cancer Cystoscopy
Slide 8: Cxbladder Market Opportunity
CXBLADDER MARKET OPPORTUNITY CXBLADDER OFFERS A SIGNIFICANT ADDRESSABLE GLOBAL MARKET ANNUALLY US$10.2b Global TAM1 PATIENT/DISEASE MANAGEMENT SURVEILLANCE (CLINICAL DECISION MAKING) (RDM2, TRM3, RECURRENCE) All Microhematuria4 Gross4 Annual cases of Population Living with bladder cancer TAM hematur
Slide 9: FY26 Financial and Operational Results
FY26 FINANCIAL AND OPERATIONAL RESULTS 9
Slide 10: FY26: Advanced Medicare Coverage with Prudent Capital Management
FY26: ADVANCED MEDICARE COVERAGE WITH PRUDENT CAPITAL MANAGEMENT 24,190 18,783 $11.5M -$35.8M $2.4M COMMERCIAL OPERATING NET LOSS AFTER 2H 26 CASH GLOBAL TESTS1 REVENUE TAX UP 19.5% BURN/MONTH -16.3% TESTS -23.8% -47.4% on on FY25 DOWN 27.7% ON on FY25 on FY25 FY25 1H 26 US Total Tests1 18,784, US C
Slide 11: Value Creation Through Three Pillars
VALUE CREATION THROUGH THREE PILLARS INPUTS OUTPUTS EXCELLENT PATIENT EXPERIENCE OUR PEOPLE AND ACCURATE RESULTS OUR IP, KNOWLEDGE EARLY DETECTION AND AND EXPERIENCE CLINICALLY ACTIONABLE CARE OUR PROCESSES INNOVATION PIPELINE FOR CLINICAL APPLICATIONS OUR CLINICAL STUDIES INCLUSIVE WORKPLACE PARTNE
Slide 12: Draft LCD Proposes Medicare Coverage for Triage and Triage Plus
DRAFT LCD PROPOSES MEDICARE COVERAGE FOR TRIAGE AND TRIAGE PLUS NOVITAS1 CONFIRMS PACIFIC EDGE CAN SUBMIT HEMATURIA TEST CLAIMS AS THEY ARE OUTSIDE PRIOR LCD2 FINALIZED LCD EXPECTED TO ACCLERATE PACIFIC EDGE’S PATH TO PROFITABILITY • Novitas has issued a draft LCD ‘Urine-based Biomarkers in Patients
Slide 13: Medicare Re-Coverage Timelines
MEDICARE RE-COVERAGE TIMELINES DRAFT LCD RELEASED, FINAL COVERAGE ESTIMATED BY END OF 2026 Novitas open meeting for draft LCD Estimated time for the LCD to become final and effective (Pacific Edge estimate) 14 May 28 June 15 May 2026 2026 2027 18 June Sept Jan 2026 2027 Date Novitas must either 2026
Slide 14: Driving Clinical Value for Physicians, Hospitals and Payers
DRIVING CLINICAL VALUE FOR PHYSICIANS, HOSPITALS AND PAYERS COMPELLING CLINICAL EVIDENCE CHANGES CLINICAL PRACTICE, MEDICAL POLICY AND GUIDELINES STUDY TEST AND EVIDENCE PUBLICATION DATE (1) • Pacific Edge generates clinical evidence required 1. STRATA Clinical Utility - CU of Triage Published May 2
Slide 15: Independent Studies Supplement Our Evidence Portfolio
INDEPENDENT STUDIES SUPPLEMENT OUR EVIDENCE PORTFOLIO INVESTIGATOR INITIATED TRIALS AND INDEPENDENT STUDIES DELIVER CLINICAL UTILITY AT MODEST SCALE INDEPENDENT STUDY FOCUS INSTITUTION TEST AND EVIDENCE TYPE PUBLICATION • Investigator initiated trials (IITs) are DATE1 Real World Utility of Triage in
Slide 16: Mounting Policy Momentum Yet to Lift US Volumes
MOUNTING POLICY MOMENTUM YET TO LIFT US VOLUMES US TOTAL TEST VOLUME1 AND COMMERCIAL PRODUCT MIX TOTAL THROUGHPUT DOWN, SALES EFFICIENCY UP 9,000 8,627 • US commercial operations challenged by Medicare non-coverage 8,000 1,072 7,335 headwinds throughout FY26 and continued into Q1 27 7,000 6,490 1,36
Slide 17: US Commercial Payers: Medicare Policy Expected to Unlock Volumes
US COMMERCIAL PAYERS: MEDICARE POLICY EXPECTED TO UNLOCK VOLUMES THE US PRIVATE HEALTH INSURANCE MARKET IS A LARGE OPPORTUNITY • Commercial payers are a significant opportunity covering almost four times more lives than Medicare 223m US private • Microhematuria patients skew younger with commercial
Slide 18: Building U.S. Commercial Payer Momentum
BUILDING U.S. COMMERCIAL PAYER MOMEMTUM MEDICARE COVERAGE UNLOCKS FURTHER COMMERCIAL PAYER POLICY Feb 2025 Triage included in Nov 2023 AUA Microhematuria Kaiser Permanente Guideline EMR integration goes live Apr 2025 ECRI rates Triage 4/5 May 2026 Sentara and BCBS Dec 2025 Kansas City Missouri Avalo
Slide 19: Targeting Intermediate Risk Microhematuria Patients
TARGETING INTERMEDIATE RISK MICROHEMATURIA PATIENTS LARGE INTERMEDIATE RISK POPULATION IS NUANCED TO ACCESS TARGETING INTERMEDIATE RISK MICROHEMATURIA PATIENTS • Intermediate risk hematuria (IRMH) patients are predominantly female • IRMH patients often stay at primary care, or are triaged at seconda
Slide 20: Intermediate Risk Microhematuria Sales Approach
INTERMEDIATE RISK MICROHEMATURIA SALES APPROACH INTEGRATED DELIVERY NETWORKS ARE THE TOP TARGET FOR INTERMEDIATE RISK MICROHEMATURIA US COMMERCIAL SALES OPERATIONS INTEGRATED DELIVERY NETWORKS • Strategic Accounts focused on IDNs (SHARE OF PATIENT VOLUME)3 • Up to 1,000 strategic accounts including
Slide 21: Implementing Clinical Pathways at Integrated Delivery Networks
IMPLEMENTING CLINICAL PATHWAYS AT INTEGRATED DELIVERY NETWORKS HELPING IDNs TO SAFELY REDUCE PATIENTS SEEN BY UROLOGISTS AND UNNECESSARY PROCEDURES PATIENT PRESENTS WITH HIGH RISK EXCLUSIONS DEFERRAL CRITERIA HEMATURIA PATIENT MANAGEMENT Exclude benign Must answer ‘No’ to all: Must answer ‘No’ to al
Slide 22: Kaiser Permanente: A Partnership with One of the Largest US Private Payers
KAISER PERMANENTE: A PARTNERSHIP WITH ONE OF THE LARGEST US PRIVATE PAYERS PILOT STUDY WITH KAISER PERMANENTE MID-ATLANTIC POINTS TO THE LARGER OPPORTUNITY KAISER PERMANENTE – REAL WORLD CLINICAL AND ECONOMIC VALUE • KP SoCal1 has 4.9 million members. The broader Kaiser system has 12.6 million membe
Slide 23: APAC Charting a Path to Profitability
APAC CHARTING A PATH TO PROFITABILITY APAC TOTAL TEST VOLUME1 AND COMMERCIAL PRODUCT MIX APAC COMMERCIAL 1,600 1,518 1,410 1,360 1,400 1,310 • APAC revenue was $2.0m in FY26 and contributed 19% of operating revenue in 1,199 1,278 1,284 1,281 141 1,168 492 2H 26, an increase from 8% in FY25 1,200 1,1
Slide 24: Consolidating New Zealand and Developing Australia and Asia
CONSOLIDATING NEW ZEALAND AND DEVELOPING AUSTRALIA AND ASIA NEW ZEALAND: SEEKING A NATIONAL HEMATURIA EVALUATION PATHWAY • ~70% of New Zealanders have access to Cxbladder testing • Cxbladder is under consideration for nationally funded clinical pathway for hematuria evaluation with Te Whatu Ora. Fun
Slide 25: Research, Development and Innovation
RESEARCH, DEVELOPMENT AND INNOVATION IDENTIFYING MARKETS WHERE WE HAVE A CREDIBLE RIGHT TO WIN THE MOLECULAR DIAGNOSTICS VALUE CHAIN LEADS OUR SEARCH FOR UNMET NEEDS RESEARCH & INNOVATION • Identify and develop substantial market opportunities where an unmet clinical need can be addressed through no
Slide 26: Next Generation Products Already Delivering Strategic Value
NEXT GENERATION PRODUCTS ALREADY DELIVERING STRATEGIC VALUE TRIAGE PLUS AND SURVEILLANCE PLUS OFFER SUPERIOR PERFORMANCE, PRICING AND MARGIN • Cxbladder Triage Plus has been analytically validated and clinically validated for all hematuria patients (MH and GH) • Triage Plus has provisional patents f
Slide 27: Expanding Market Opportunities with Innovation
EXPANDING MARKET OPPORTUNITIES WITH INNOVATION DEVELOPING AN IVD1 IS THE PRIMARY AVENUE FOR INTERNATIONAL OPPORTUNITIES ADVANCING IVD DEVELOPMENT FOR INTERNATIONAL MARKETS • Pacific Edge is following a well-worn model of development and execution in the US with a CAP/CLIA-approved LDT2 providing ser
Slide 28: FY26 Financial Performance
FY26 FINANCIAL PERFORMANCE 28
Slide 29: Positioning Pacific Edge for Medicare Re-Coverage
POSITIONING PACIFIC EDGE FOR MEDICARE RE-COVERAGE COST SAVINGS MINIMIZE CASH BURN 2H 26 1H 26 FY26 FY25 2H 26 vs FY26 vs • Operating revenue fell after loss of Financial Period ($000) Medicare and Medicare Advantage (Unaudited) (Unaudited) (Audited) (Audited) 1H 26 FY25 coverage and reduced test vol
Slide 30: Operating Expenses
OPERATING EXPENSES ALL COSTS REDUCED WITH LARGEST REDUCTION IN SALES AND MARKETING 2H 26 1H 26 FY26 FY25 2H 26 vs. FY26 vs. Operating expenses have reduced by 9.5% on Financial Period ($000)1 FY25 through careful expense management (Unaudited) (Unaudited) (Audited) (Audited) 1H 26 FY25 targeting cap
Slide 31: Outlook
OUTLOOK G+ | PacificEdge’
Slide 32: Outlook
OUTLOOK POSITIONED TO UNLOCK VALUE THROUGH UPCOMING COMMERCIAL, CLINICAL AND INNOVATION MILESTONES INNOVATION DRIVES LONG-TERM CLINICAL EVIDENCE DRIVES VALUE CREATION COMMERCIAL CATALYSTS FOR NEAR- MEDIUM-TERM VALUE CREATION • Next generation products demonstrate superior TERM VALUE CREATION perform
Slide 33: Appendix
APPENDIX G+ | PacificEdge’
Slide 34: The Cxbladder Suite
THE CXBLADDER SUITE Hematuria Evaluation NMIBC1 Surveillance Cxbladder Product Triage Detect Triage Plus Monitor Surveillance Plus Product Summary Risk stratification of Adjunctive use with Risk stratification and Alternative to cystoscopy Alternative to cystoscopy for microhematuria patients to cys
Slide 35: Hematuria Evaluation Five Year Clinical Studies Roadmap
HEMATURIA EVALUATION FIVE YEAR CLINICAL STUDIES ROADMAP Pre Calendar year 2023 2024 2025 2026 2027 2028 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 DBL STRATA * DBL DRIVE * AUSSIE * microDRIVE * Pooled CV CREDIBLE * Legend: Pre-activation (docs, CTA etc) Publication Submit
Slide 36: Surveillance Five Year Clinical Studies Roadmap
SURVEILLANCE FIVE YEAR CLINICAL STUDIES ROADMAP Pre Calendar year 2023 2024 2025 2026 2027 2028 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 “The 1800”1 LOBSTER * OCTOPUS CAB2 * Legend: Pre-activation (docs, CTA etc) Publication Submitted Records review / follow-up * SIV DB
Slide 37: Sources and Assumptions - Total Addressable Market (US)
SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (US) REGION STATISTIC SOURCE Population 341,762,685 https://www.census.gov/popclock/ Presentation from Dr Sia Daneshmand (Director of Incidence of hematuria 7,000,000 Urologic Oncology and Clinical Research, USC) July 2019 Presentation from Dr Sia D
Slide 38: Sources and Assumptions - Total Addressable Market (Europe)
SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (EUROPE) REGION STATISTIC SOURCE 600,000,000 World-population - Europe Population World-population - Russia Incidence of hematuria 12,000,000 Science Direct Presentation from Dr Sia Daneshmand (Director of Referred for clinical workup 6,000,000 Urol
Slide 39: Sources and Assumptions - Total Addressable Market (APAC)
SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (APAC) REGION STATISTIC SOURCE 830,000,000World population - Southeast Asia Population Population Pyramid - Japan Population Pyramid - Hong Kong Incidence of hematuria 16,600,000Science Direct Presentation from Dr Sia Daneshmand (Director of 8,300,0
Slide 40: For More Information
FOR MORE INFORMATION: Dr. Peter Meintjes Chief Executive Officer email: peter.meintjes@pelnz.com Grant Gibson Chief Financial Officer email: grant.gibson@pelnz.com Pacific Edge 87 St David Street, PO Box 56, Dunedin, New Zealand P +64 3 577 6733 Within NZ 0800 555 563 email: investors@pacificedge.co